[Public Notice+] Jinwon Life Sciences Signs $1.8 Million Plasmid DNA Drug Supply Contract
[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 19th that it has signed a plasmid DNA drug supply contract worth $1.8 million with a U.S. biotech company. The contracting party has not been disclosed according to the contract, and the total contract amount is approximately 2.2 billion KRW when converted to Korean won.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
GeneOne Life Science produces and supplies top-quality plasmid DNA drugs through its subsidiary VGXI, a cGMP (current Good Manufacturing Practice) contract manufacturing facility located in Houston, USA. To respond to the increasing demand for plasmid DNA drugs, expansion of the facility is also underway.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
